Page last updated: 2024-11-06

2,6-dihydroxyacetophenone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,6-Dihydroxyacetophenone, also known as resacetophenone, is a naturally occurring phenolic compound found in various plants. It exhibits a range of biological activities, including antioxidant, anti-inflammatory, and antimicrobial properties. Its synthesis can be achieved through various methods, such as the Fries rearrangement of resorcinol acetate or the condensation of resorcinol with acetic anhydride. 2,6-Dihydroxyacetophenone has been studied for its potential therapeutic applications in treating conditions like inflammation, oxidative stress, and infections. Its antioxidant properties are attributed to its ability to scavenge free radicals, while its anti-inflammatory effects may be related to its inhibition of pro-inflammatory enzymes. The compound's antimicrobial activity has been demonstrated against a variety of bacterial and fungal species. Research into 2,6-dihydroxyacetophenone continues to explore its pharmacological potential and its role in traditional medicine.'

2,6-dihydroxyacetophenone: inhibits aminopyrine-N-demethylase in rat liver microsomal preparations [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID69687
CHEMBL ID454739
CHEBI ID173644
SCHEMBL ID105807
MeSH IDM0071729

Synonyms (78)

Synonym
BIDD:ER0607
CHEBI:173644
1-(2,6-dihydroxy-phenyl)-ethanone
AB-131/40185723
1-(2,6-dihydroxyphenyl)ethanone
.gamma.-resacetophenone
2',6'-dihydroxyacetophenone
2-acetylresorcinol
ethanone,6-dihydroxyphenyl)-
699-83-2
resorcinol, 2-acetyl-
nsc-615
2,6-dihydroxyacetophenone
acetophenone,6'-dihydroxy-
nsc615
2',6'-dihydroxyacetophenone, 97%
NCGC00166008-01
D-3400
AC-10724
2'',6''-dihydroxyacetophenone
2, 6-dihydroxyacetophenone
bdbm50249071
AKOS000299253
CHEMBL454739 ,
2,6-dihydroxy acetophenone
inchi=1/c8h8o3/c1-5(9)8-6(10)3-2-4-7(8)11/h2-4,10-11h,1h3
yptjkhvbdcrknf-uhfffaoysa-
D1716
A836723
gamma-resacetophenone
acetophenone, 2',6'-dihydroxy-
1,3-benzenediol, 2-acetyl-
ec 211-833-6
88bo51g3y2 ,
nsc 615
einecs 211-833-6
unii-88bo51g3y2
ethanone, 1-(2,6-dihydroxyphenyl)-
1-(2,6-dihydroxyphenyl)ethan-1-one
2-acetyl resorcinol
FT-0610665
FS-2546
acetophenone, 2,6-dihydroxy-
sodium cromoglicate impurity a [ep impurity]
2',6'-dihydroxy-acetophenone
(2',6'-dihydroxy)acetophenone
mono acetyl resorcinol
1-(2,6-dihydroxyphenyl)-ethanone
SCHEMBL105807
mfcd00002270
2 inverted exclamation mark ,6 inverted exclamation mark -dihydroxyacetophenone
SY001633
DTXSID00220185
acetyl-2,6-dihydroxybenzene
W-203531
CS-W019984
2',6'-dihydroxyacetophenone, matrix substance for maldi-ms, >=99.5%
2',6'-dihydroxyacetophenone, matrix substance for maldi-ms, >=99.5% (hplc), ultra pure
sodium cromoglicate imp. a (ep); 1-(2,6-dihydroxyphenyl)ethanone; 2',6'-dihydroxyacetophenone; sodium cromoglicate impurity a
1-(2,6-dihydroxyphenyl)ethanone (2',6'-dihydroxyacetophenone)
2`,6`-dihydroxyacetophenone
2-acetyl-1,3-dihydroxybenzene
laquo gammaraquo -resacetophenone
acetophenone, 2',6'-dihydroxy- (8ci)
2-acetyl-resorcinol
ethanone, 1-(2,6-dihydroxyphenyl)- (9ci)
1-(2,6-dihydroxyphenyl)ethanone, 9ci
2-acetyl-1,3-benzenediol
AMY21894
STL195537
Q27269919
HY-Y0106
CK2557
9EQ ,
1-[2,6-bis(oxidanyl)phenyl]ethanone
EN300-114470
PD158440
Z1255485184
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic ketoneA ketone in which the carbonyl group is attached to an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
phosphopantetheinyl transferaseBacillus subtilisPotency25.11890.141337.9142100.0000AID1490
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency446.68400.010039.53711,122.0200AID1479
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.84890.00798.23321,122.0200AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)300.00000.03403.987110.0000AID1272598
Solute carrier family 28 member 3Homo sapiens (human)Ki100.00002.10002.75003.4000AID370698
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 28 member 3Homo sapiens (human)
xenobiotic transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine nucleobase transportSolute carrier family 28 member 3Homo sapiens (human)
uridine transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
sodium ion transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine-containing compound transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
nucleoside transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
purine nucleobase transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
pyrimidine nucleoside transportSolute carrier family 28 member 3Homo sapiens (human)
purine nucleoside transmembrane transportSolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
purine nucleobase transmembrane transporter activitySolute carrier family 28 member 3Homo sapiens (human)
nucleoside:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
protein bindingSolute carrier family 28 member 3Homo sapiens (human)
uridine transmembrane transporter activitySolute carrier family 28 member 3Homo sapiens (human)
purine-specific nucleoside:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
pyrimidine- and adenosine-specific:sodium symporter activitySolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneSolute carrier family 28 member 3Homo sapiens (human)
plasma membraneSolute carrier family 28 member 3Homo sapiens (human)
brush border membraneSolute carrier family 28 member 3Homo sapiens (human)
plasma membraneSolute carrier family 28 member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID337495Antimicrobial activity against Streptococcus durans NCTC 8307 after 24 hrs by agar dilution method
AID1374944Inhibition of mouse tyrosinase2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Melanogenesis inhibitory pregnane glycosides from Cynanchum atratum.
AID337497Antimicrobial activity against Candida albicans 3110 after 24 hrs by agar dilution method
AID337496Antimicrobial activity against Candida albicans 3153 after 24 hrs by agar dilution method
AID395642Activity of Crotalus adamanteus venom PLA2 assessed as 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol hydrolysis at 0.15 uM2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds.
AID337754Antimicrobial activity against Candida albicans ATCC 12301 after 24 hrs by agar dilution method
AID1150149In vivo inhibition of mixed function oxidase system in rat assessed as prolongation of hexobarbital-induced sleeping time at 100 mg/kg, ip pretreated for 10 mins followed by hexobarbital-challenge relative to control1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Inhibitors of hepatic mixed function oxidase. 3. Inhibition of hepatic microsomal aniline hydroxylase and aminopyrine demethylase by 2,6- and 2,4-dihydroxyphenyl alkyl ketones and related compounds.
AID1150147Inhibition of aminopyrine demethylase activity of mixed function oxidase system in Wistar rat liver microsomes assessed as conversion of aminopyrine to 4-aminoantipyrine after 20 mins1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Inhibitors of hepatic mixed function oxidase. 3. Inhibition of hepatic microsomal aniline hydroxylase and aminopyrine demethylase by 2,6- and 2,4-dihydroxyphenyl alkyl ketones and related compounds.
AID395645Inhibition of Crotalus adamanteus venom PLA2 assessed as effect on 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol hydrolysis at 0.30 uM2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds.
AID395644Inhibition of Crotalus adamanteus venom PLA2 assessed as effect on 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol hydrolysis at 0.15 uM2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds.
AID395643Activity of Crotalus adamanteus venom PLA2 assessed as 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-3-phosphoglycerol hydrolysis at 0.30 uM2009European journal of medicinal chemistry, Jan, Volume: 44, Issue:1
Molecular modeling and inhibition of phospholipase A2 by polyhydroxy phenolic compounds.
AID337494Antimicrobial activity against Bacillus subtilis NCTC 10400 after 24 hrs by agar dilution method
AID1150146Inhibition of aniline hydroxylase activity of mixed function oxidase system in Wistar rat liver microsomes assessed as conversion of aniline to p-aminophenol after 10 mins1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Inhibitors of hepatic mixed function oxidase. 3. Inhibition of hepatic microsomal aniline hydroxylase and aminopyrine demethylase by 2,6- and 2,4-dihydroxyphenyl alkyl ketones and related compounds.
AID1918888Induction of adipogenesis in differentiated human BMMSC cells assessed as increase in adiponectin level at 30 uM in presence of IDX by ELISA2022Journal of natural products, 12-23, Volume: 85, Issue:12
Discovery of Pan-peroxisome Proliferator-Activated Receptor Modulators from an Endolichenic Fungus,
AID337493Antimicrobial activity against Staphylococcus aureus NCTC 6571 after 24 hrs by agar dilution method
AID1150150In vivo inhibition of mixed function oxidase system in rat assessed as increase in zoxazolamine-induced paralysis time at 100 mg/kg, ip pretreated for 10 mins followed by zoxazolamine-challenge relative to control1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Inhibitors of hepatic mixed function oxidase. 3. Inhibition of hepatic microsomal aniline hydroxylase and aminopyrine demethylase by 2,6- and 2,4-dihydroxyphenyl alkyl ketones and related compounds.
AID370698Binding affinity to human recombinant CNT3 expressed in pig PK15NTD cells assessed as [3H]uridine uptake by beta-scintillation counter2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors.
AID1272598Inhibition of mushroom tyrosinase using L-tyrosine as substrate after 20 mins by spectrophotometric method2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
One-pot green synthesis of 1,3,5-triarylpentane-1,5-dione and triarylmethane derivatives as a new class of tyrosinase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (39)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.56)18.7374
1990's2 (5.13)18.2507
2000's12 (30.77)29.6817
2010's17 (43.59)24.3611
2020's7 (17.95)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.40 (24.57)
Research Supply Index3.74 (2.92)
Research Growth Index5.34 (4.65)
Search Engine Demand Index32.77 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.44%)6.00%
Case Studies1 (2.44%)4.05%
Observational0 (0.00%)0.25%
Other39 (95.12%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]